Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
The management of Crohn's disease is rapidly changing. The advent of potent immunomodulatory and biologic therapies has led to more demanding endpoints for clinical trials than only clinical response and remission. Complete withdrawal of corticosteroids, healing of endoscopically visible lesion...
Principais autores: | D'Haens, G, Fedorak, R, Lémann, M, Feagan, BG, Kamm, M, Cosnes, J, Rutgeerts, P, Marteau, P, Travis, S, Schölmerich, J, Hanauer, S, Sandborn, W |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2009
|
Registros relacionados
-
Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
por: Gottlieb, K, et al.
Publicado em: (2015) -
Evolving concepts in phases I and II drug development for Crohn's Disease
por: Jairath, V, et al.
Publicado em: (2016) -
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
por: Peyrin-Biroulet, L, et al.
Publicado em: (2012) -
Development of the Crohn's disease digestive damage score, the Lemann score.
por: Pariente, B, et al.
Publicado em: (2011) -
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
por: Gasche, C, et al.
Publicado em: (2000)